174 related articles for article (PubMed ID: 12939544)
21. Clinical pharmacokinetics of salmeterol.
Cazzola M; Testi R; Matera MG
Clin Pharmacokinet; 2002; 41(1):19-30. PubMed ID: 11825095
[TBL] [Abstract][Full Text] [Related]
22. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.
Mahler DA; Waterman LA; Ward J; Gifford AH
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):103-9. PubMed ID: 23745526
[TBL] [Abstract][Full Text] [Related]
23. Salmeterol vs theophylline: sleep and efficacy outcomes in patients with nocturnal asthma.
Wiegand L; Mende CN; Zaidel G; Zwillich CW; Petrocella VJ; Yancey SW; Rickard KA
Chest; 1999 Jun; 115(6):1525-32. PubMed ID: 10378544
[TBL] [Abstract][Full Text] [Related]
24. [Long-acting beta 2-stimulants].
Tamura G
Nihon Rinsho; 2001 Oct; 59(10):1973-8. PubMed ID: 11676141
[TBL] [Abstract][Full Text] [Related]
25. Inhaled fluticasone and salmeterol suppress eosinophilic airway inflammation in chronic obstructive pulmonary disease: relations with lung function and bronchodilator reversibility.
Perng DW; Wu CC; Su KC; Lee YC; Perng RP; Tao CW
Lung; 2006; 184(4):217-22. PubMed ID: 17006748
[TBL] [Abstract][Full Text] [Related]
26. Long-acting inhaled beta2-agonists in asthma therapy.
Moore RH; Khan A; Dickey BF
Chest; 1998 Apr; 113(4):1095-108. PubMed ID: 9554653
[TBL] [Abstract][Full Text] [Related]
27. Effect of salmeterol compared with beclomethasone on allergen-induced asthmatic and inflammatory responses.
Pizzichini MM; Kidney JC; Wong BJ; Morris MM; Efthimiadis A; Dolovich J; Hargreave FE
Eur Respir J; 1996 Mar; 9(3):449-55. PubMed ID: 8730003
[TBL] [Abstract][Full Text] [Related]
28. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
Spencer S; Evans DJ; Karner C; Cates CJ
Cochrane Database Syst Rev; 2011 Oct; (10):CD007033. PubMed ID: 21975759
[TBL] [Abstract][Full Text] [Related]
29. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.
Frois C; Wu EQ; Ray S; Colice GL
Clin Ther; 2009 Dec; 31(12):2779-803. PubMed ID: 20110019
[TBL] [Abstract][Full Text] [Related]
30. Salmeterol xinafoate in asthma.
Palmer JB; Oxford JM
JAMA; 1994 Nov 23-30; 272(20):1575-6. PubMed ID: 7966861
[No Abstract] [Full Text] [Related]
31. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol.
Lipworth BJ; Aziz I
J Allergy Clin Immunol; 1999 Jan; 103(1 Pt 1):88-92. PubMed ID: 9893190
[TBL] [Abstract][Full Text] [Related]
32. Long acting beta-agonists versus theophylline for maintenance treatment of asthma.
Wilson AJ; Gibson PG; Coughlan J
Cochrane Database Syst Rev; 2000; (2):CD001281. PubMed ID: 10796631
[TBL] [Abstract][Full Text] [Related]
33. The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease.
Chapman KR; Arvidsson P; Chuchalin AG; Dhillon DP; Faurschou P; Goldstein RS; Kuipers AF;
Can Respir J; 2002; 9(3):178-85. PubMed ID: 12068339
[TBL] [Abstract][Full Text] [Related]
34. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma.
Markham A; Jarvis B
Drugs; 2000 Nov; 60(5):1207-33. PubMed ID: 11129128
[TBL] [Abstract][Full Text] [Related]
35. Effects on resource utilization of adding salmeterol in combination or separately to inhaled corticosteroids.
Chan J; Hui RL; Spence MM
J Manag Care Pharm; 2007; 13(1):21-7. PubMed ID: 17269833
[TBL] [Abstract][Full Text] [Related]
36. A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease.
Sovani MP; Whale CI; Tattersfield AE
Drug Saf; 2004; 27(10):689-715. PubMed ID: 15350154
[TBL] [Abstract][Full Text] [Related]
37. Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids.
Dempsey OJ; Wilson AM; Sims EJ; Mistry C; Lipworth BJ
Chest; 2000 Apr; 117(4):950-3. PubMed ID: 10767223
[TBL] [Abstract][Full Text] [Related]
38. Tiotropium versus salmeterol in COPD.
Schembri S
N Engl J Med; 2011 Jun; 364(26):2553; author reply 2553-4. PubMed ID: 21714655
[No Abstract] [Full Text] [Related]
39. Efficacy and safety of salmeterol in childhood asthma.
Lenney W; Pedersen S; Boner AL; Ebbutt A; Jenkins MM
Eur J Pediatr; 1995 Dec; 154(12):983-90. PubMed ID: 8801107
[TBL] [Abstract][Full Text] [Related]
40. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency.
Palmqvist M; Persson G; Lazer L; Rosenborg J; Larsson P; Lötvall J
Eur Respir J; 1997 Nov; 10(11):2484-9. PubMed ID: 9426083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
